VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS10059685 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
TVIS10059683 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
TVIS10059682 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
TVIS10059684 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
TVIS30050045 | HIV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
TVIS20014252 | HPV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
TVIS20066584 | HPV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | XDH |
---|---|
DrugBank ID | DB04854 |
Drug Name | Febuxostat |
Target ID | BE0002204 |
UniProt ID | P47989 |
Regulation Type | inhibitor |
PubMed IDs | 23286293; 25501928; 16958189; 19337428 |
Citations | Saban-Ruiz J, Alonso-Pacho A, Fabregate-Fuente M, de la Puerta Gonzalez-Quevedo C: Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):94-9.@@Nishino T, Okamoto K: Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. J Biol Inorg Chem. 2015 Mar;20(2):195-207. doi: 10.1007/s00775-014-1210-x. Epub 2014 Dec 12.@@Pohar S, Murphy G: Febuxostat for prevention of gout attacks. Issues Emerg Health Technol. 2006 Aug;(87):1-4.@@Hu M, Tomlinson B: Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1209-20. doi: 10.2147/tcrm.s3310. |
Groups | Approved |
Direct Classification | Thiazolecarboxylic acids and derivatives |
SMILES | CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N |
Pathways | |
PharmGKB | PA165958521 |
ChEMBL | CHEMBL1164729 |